MedPlus Health Services Limited disclosed on April 07, 2026, that its promoters have not created any new encumbrances on their shareholdings during the quarter ended March 31, 2026. The declarations were submitted in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. This disclosure assures investors that the promoter group's shareholding remains free from additional charges or pledges beyond those previously reported in the financial year.

The declarations were received from three key promoter entities: Gangadi Madhukar Reddy, Agilemed Investments Private Limited, and Lone Furrow Investments Private Limited. Each entity confirmed that no direct or indirect encumbrances were established on the shares held by them during the specified period. The only encumbrances in effect are those that had already been disclosed to the exchanges during the Financial Year 2025-26.

Promoter Declarations

The following table details the promoters who submitted the declarations for the period ended March 31, 2026:

The confirmations were addressed to the Audit Committee of MedPlus Health Services Limited and subsequently forwarded to BSE Limited and National Stock Exchange of India Limited. Manoj Kumar Srivastava, Company Secretary & Compliance Officer, filed the intimation on behalf of the company.

MedPlus Health Services reported a strong financial performance for the quarter and financial year ended March 31, 2026. The company's revenue for Q4 FY26 stood at ₹18,644m, marking a 23.5% increase compared to the same period in the previous year. Sequentially, revenue grew by 3.2% from the preceding quarter. The full fiscal year 2026 revenue reached ₹68,925m, a 12.3% increase over FY25. The Board of Directors approved the audited standalone and consolidated financial results for the period at a meeting held on May 20, 2026. The extract of these results was published in Financial Express and Nava Telangana on May 22, 2026, pursuant to Regulation 47 of SEBI LODR.

Financial Performance

The company's profitability metrics improved during the period. Net profit for Q4 FY26 was ₹640m, up 24.6% year-on-year. For the full year, net profit surged 46.2% to ₹2,196.1m. EBITDA for the quarter rose to ₹1.898B compared to ₹1.522B in Q4 FY25, with the EBITDA margin improving to 10.2% from 10.1% year-on-year. Operating EBITDA for the quarter stood at ₹1,076m, representing a margin of 5.8%, compared to 5.3% in Q4 FY25. On a full-year basis, operating EBITDA stood at ₹3,658m with a margin of 5.3%.

The following table summarises the key financial metrics for the quarter:

Operational Highlights

MedPlus expanded its store network significantly during the fiscal year. The company added 618 stores on a net basis, bringing the total count to 5,330 stores as of March 31, 2026. In Q4 FY26 alone, the company added 218 stores net, with 295 gross additions and 77 closures. The expansion strategy focused on deeper penetration in existing clusters and growth beyond Tier-One cities, with 384 net additions recorded beyond Tier-One areas during the year. For FY27, the company plans to open 800 net new stores, including franchisee outlets.

Segment and Store Metrics

The pharmacy segment remained the primary revenue driver, contributing ₹18,266m in revenue for Q4 FY26. Stores older than 12 months demonstrated strong operational efficiency, reporting a store-level EBITDA margin of 13.1% and an operating ROCE of 80.0% for the quarter. The company's gross margin for the quarter improved to 26.5%, while the full-year gross margin stood at 26.2%, an increase of 180 basis points over FY25. The diagnostics segment recorded an operating EBITDA of ₹53.1m for the quarter, representing a margin of 15.3%.